🧠 Three Translational Pillars: From Discovery Mass Spec to Clinical Bedside
Translational Oncology PipelineWHO CNS5 Glioma Integrated Subtyping
Integrating proteomic phosphorylation signatures and metabolomic D-2-hydroxyglutarate (D-2HG) accumulation to classify Astrocytoma IDH-mutant, Oligodendroglioma 1p/19q-codeleted, and Glioblastoma IDH-wildtype.
Skyline MRM & PRM Multiplex Verification
Transitioning from untargeted discovery into targeted clinical assays: transition selection, heavy isotope-labeled internal standards (AQUA), collision energy optimization, and lower limit of quantification (LLOQ) validation.
LDT vs. IVD & Molecular Tumor Board
Overcoming pre-analytical cold ischemia drift, achieving CLIA/CAP analytical validity (precision, linearity, recovery), and synthesizing multi-omics findings into actionable molecular tumor board recommendations.
12 Modular Curriculum Chapters
Comprehensive practical manuals covering Orbitrap DDA/DIA mass spec, MSFragger LFQ, XCMS 3 metabolomics, machine learning biomarker panels, Skyline targeted PRM/MRM, and WHO CNS5 translation.
Module 1: Beyond the Genome: The Functional Proteome, Metabolome & PTM Landscape in Oncology
Biological rationale for clinical mass spectrometry: why genomic DNA mutations alone fail to predict phenotype, kinase post-translational modifications (PTMs), oncometabolites, Warburg rewiring, and intratumoral heterogeneity.
Module 2: Clinical Mass Spectrometry Foundations: LC-MS/MS Instrumentation, Orbitraps & DDA vs. DIA
Principles of high-resolution mass spectrometry: nanoflow electrospray ionization (nanoESI), quadrupole mass filters, Orbitrap and Time-of-Flight (TOF) analyzers, and Data-Dependent Acquisition (DDA) vs. Data-Independent Acquisition (DIA/SWATH).
Module 3: Clinical Study Design, Biospecimen Quality Control & WHO CNS5 Brain Tumor Cohort Mapping
Pre-analytical biospecimen variables in translational oncology: cold ischemia impact, freeze-thaw cycles, biobanking SOPs, and the 2021 WHO CNS5 classification of adult-type diffuse gliomas.
Module 4: Proteomics Identification & Quantification: Database Searching, Target-Decoy FDR & LFQ
Computational identification of peptide spectra: cross-correlation scoring, false discovery rate (FDR) target-decoy benchmarking, protein parsimony inference, and label-free quantification (LFQ).
Module 5: Untargeted Metabolomics Processing: Peak Picking, Alignment & MSI Spectral Identification
High-throughput untargeted metabolomics data processing: XCMS feature detection, retention time alignment, adduct deconvolution, and Metabolomics Standards Initiative (MSI) confidence levels.
Module 6: Statistical Preprocessing & Cancer Signatures: Imputation, ComBat & Volcano Prioritization
Defensive biostatistics for mass spectrometry: Left-censored missing value imputation, ComBat batch adjustment, linear modeling with limma/MSstats, and pathway enrichment in cancer metabolism.
Module 7: The Biomarker Attrition Funnel: Translating Discovery Omics Lists into Diagnostic Panels
Overcoming the biomarker translational gap: the clinical attrition funnel from 5,000 discovery features to 5-10 validated markers, biological plausibility filtering, secretome dynamics, and stability assays.
Module 8: Machine Learning for Biomarker Panels: PLS-DA, Random Forests & Overfitting Prevention
Designing multi-marker clinical classifier panels using supervised machine learning: Partial Least Squares Discriminant Analysis (PLS-DA), Random Forest Boruta selection, nested cross-validation, and ROC/AUC metrics.
Module 9: Targeted Mass Spectrometry: SRM/MRM, PRM Assays & Skyline Workspace Design
Transition from discovery to targeted clinical assays: Triple Quadrupole Selected Reaction Monitoring (SRM/MRM), Orbitrap Parallel Reaction Monitoring (PRM), stable isotope-labeled internal standards (SIL/AQUA), and Skyline assay design.
Module 10: Analytical & Clinical Validation Rigor: Calibration, LOD/LOQ & Diagnostic PPV/NPV
Rigorous analytical assay qualification following FDA bioanalytical guidelines: standard calibration curves, lower limit of detection (LOD), lower limit of quantification (LOQ), matrix effects, and ROC-derived clinical cut-offs.
Module 11: Regulatory Landscapes & Clinical Implementation: LDT vs. IVD, CLIA/CAP & Reimbursement
Navigating clinical adoption: Laboratory Developed Tests (LDTs) under CLIA/CAP vs. FDA In Vitro Diagnostics (IVD), companion diagnostics (CDx) co-development with targeted therapeutics, and health economic CPT coding.
Module 12: Integrative Multi-Omics Case Studies: WHO CNS5 Glioma Subtyping & Therapy Monitoring
Hands-on clinical synthesis: integrating quantitative D-2-hydroxyglutarate (D-2HG) oncometabolite profiling with targeted IDH1-R132H PRM assays, longitudinal liquid biopsy monitoring, and Molecular Tumor Board reporting.